4Schmitt J,Spuls PI,Thomas KS,et al. The Harmonising OutcomeMeasures for Eczema ( HOME) statement to assess clinical signs of atop-ic eczema in trials [ J ]. J Allergy Clin Immunol, 2014, 134 (4 ) : 800-807.
5Gola M, Milanesi N, D'Erme AM. Clinical evaluation and assessmentof the therapeutic efficacy of alitretinoin in a group of patients with chro-nic hand eczema refractory to topical steroid therapy [J], G Ital Derma-tol Venereol, 2014,149(4) :435 -439.
6Inan S,Dun NJ,Cowan A. Inhibitory effect of lidocaine on pain anditch using formalin-induced nociception and 5 ^guanidinonaltrindole-in-duced scratching models in mice: behavioral and neuroanatomical evi-dence [ J ].Eur J Pharmacol, 2009,616( 1-3 ) :141 - 146.
7Olsen PC, Ferreira TP, Serra MF, et al. Lidocaine-derivative JMF2-1prevents ovalbumin-induced airway inflammation by regulating the functionand survival of T cells [ J]. Clin Exp Allergy, 2011,41 (2) :250 - 259.
8Kawasaki T, Kawasaki C, Sata T, et al. Lidocaine suppresses mousePeyer,s Patch T cell functions and induces bacterial translocation Surger-y, 2011,149(1):106 -113.
